Abstract
Large-scale RNAi screens (i.e., genome-wide arrays and pools) can reveal the essential biological functions of previously uncharacterized genes. Due to the nature of the selection process involved in screens, RNAi screens are also very useful for identifying genes involved in drug responses. The information gained from these screens could be used to predict a cancer patient’s response to a specific drug (i.e., precision medicine) or identify anti-cancer drug resistance genes, which could be targeted to improve treatment outcomes. In this capacity, screens have been most often performed in vitro. However, there is limitation to performing these screens in vitro: genes which are required in only an in vivo setting (e.g., rely on the tumor microenvironment for function) will not be identified. As such, it can be desirable to perform RNAi screens in vivo. Here we outline the additional technical details that should be considered for performing genome-wide RNAi drug screens of cancer cells under in vivo conditions (i.e., tumor xenografts).
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Jameson JL, Longo DL (2015) Precision medicine – personalized, problematic, and promising. N Engl J Med 372(23):2229–2234. https://doi.org/10.1056/NEJMsb1503104
Hu G, Luo J (2012) A primer on using pooled shRNA libraries for functional genomic screens. Acta Biochim Biophys Sin Shanghai 44(2):103–112. https://doi.org/10.1093/abbs/gmr116
Lenoir WF, Lim TL, Hart T (2018) PICKLES: the database of pooled in-vitro CRISPR knockout library essentiality screens. Nucleic Acids Res 46(D1):D776–D780. https://doi.org/10.1093/nar/gkx993
Tu MM, Lee FYF, Jones RT et al (2019) Targeting DDR2 enhances tumor response to anti–PD-1 immunotherapy. Sci Adv 5(2). https://doi.org/10.1126/sciadv.aav2437
Wolf J, Müller-Decker K, Flechtenmacher C et al (2014) An in vivo RNAi screen identifies SALL1 as a tumor suppressor in human breast cancer with a role in CDH1 regulation. Oncogene 33(33):4273–4278. https://doi.org/10.1038/onc.2013.515
Workenhe ST, Ketela T, Moffat J et al (2016) Genome-wide lentiviral shRNA screen identifies serine/arginine-rich splicing factor 2 as a determinant of oncolytic virus activity in breast cancer cells. Oncogene 35(19):2465–2474. https://doi.org/10.1038/onc.2015.303
Sasaki K, Kurahara H, Young ED et al (2017) Genome-wide in vivo RNAi screen identifies ITIH5 as a metastasis suppressor in pancreatic cancer. Clin Exp Metastasis 34(3–4):229–239. https://doi.org/10.1007/s10585-017-9840-3
Iskit S, Lieftink C, Halonen P et al (2016) Integrated in vivo genetic and pharmacologic screening identifies co-inhibition of EGRF and ROCK as a potential treatment regimen for triple-negative breast cancer. Oncotarget 7(28):42859–42872. https://doi.org/10.18632/oncotarget.10230
Geng R, Tan X, Zuo Z et al (2017) Synthetic lethal short hairpin RNA screening reveals that ring finger protein 183 confers resistance to trametinib in colorectal cancer cells. Chin J Cancer 36(1):63. https://doi.org/10.1186/s40880-017-0228-1
Schaefer C, Mallela N, Seggewiß J et al (2018) Target discovery screens using pooled shRNA libraries and next-generation sequencing: a model workflow and analytical algorithm. PLoS One 13(1). https://doi.org/10.1371/journal.pone.0191570
Gargiulo G, Serresi M, Cesaroni M et al (2014) In vivo shRNA screens in solid tumors. Nat Protoc 9(12):2880–2902. https://doi.org/10.1038/nprot.2014.185
Marcato P, Dean CA, Liu RZ et al (2015) Aldehyde dehydrogenase 1A3 influences breast cancer progression via differential retinoic acid signaling. Mol Oncol 9(1):17–31. https://doi.org/10.1016/j.molonc.2014.07.010
Strezoska Ž, Licon A, Haimes J et al (2012) Optimized PCR conditions and increased shRNA fold representation improve reproducibility of pooled shRNA screens. PLoS One 7(8). https://doi.org/10.1371/journal.pone.0042341
Islam MF, Watanabe A, Wong L et al (2017) Enhancing the throughput and multiplexing capabilities of next generation sequencing for efficient implementation of pooled shRNA and CRISPR screens. Sci Rep 7(1):1–12. https://doi.org/10.1038/s41598-017-01170-z
Amer MH, White LJ, Shakesheff KM (2015) The effect of injection using narrow-bore needles on mammalian cells: administration and formulation considerations for cell therapies. J Pharm Pharmacol 67(5):640–650. https://doi.org/10.1111/jphp.12362
Kampmann M, Horlbeck MA, Chen Y et al (2015) Next-generation libraries for robust RNA interference-based genome-wide screens. Proc Natl Acad Sci U S A 112(26):E3384–E3391. https://doi.org/10.1073/pnas.1508821112
Acknowledgments
P.M. is funded by a grant support from the Canadian Institutes of Health Research (CIHR, PJT 162313). M.L.D. was supported by Nova Scotia Research and Innovation Graduate and Killam Laureate scholarships. M.L.D. was also supported by CGS-D award from the CIHR.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2021 The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature
About this protocol
Cite this protocol
Dahn, M.L., Marcato, P. (2021). In Vivo Genome-Wide Pooled RNAi Screens in Cancer Cells to Identify Determinants of Chemotherapy/Drug Response. In: Vizeacoumar, F.J., Freywald, A. (eds) Mapping Genetic Interactions. Methods in Molecular Biology, vol 2381. Humana, New York, NY. https://doi.org/10.1007/978-1-0716-1740-3_10
Download citation
DOI: https://doi.org/10.1007/978-1-0716-1740-3_10
Published:
Publisher Name: Humana, New York, NY
Print ISBN: 978-1-0716-1739-7
Online ISBN: 978-1-0716-1740-3
eBook Packages: Springer Protocols